According to Nobel Prize of Medicine 1996, Peter C. Doherty, synchrotron light is present at 80% of drugs discovery and development. But which techniques are the most appropriate? Which type of analysis can be performed? Which are the advantages of using synchrotron light for pharmaceutical companies?
For clarifying these and other points, the ALBA Synchrotron organises next 7th May a workshop addressed to companies of the biomedical sector. The purpose of the event is to inform about the type of data that can be obtained using the available techniques at the ALBA's beamlines as well as talking about specific examples of experiments performed at ALBA and other worldwide synchrotron facilities.
The event includes presentations by ALBA researchers (pointing out the characterisation of active principles and the structural biology for drug design) and by pharmaceutical companies that have already collaborated with the ALBA Synchrotron – like Almirall or Enantia -. It is also included a visit to ALBA's facilities and areas of discussion and networking to promote the exchange of ideas between ALBA scientists and attendants.
The event has no registration fees. However, it is compulsory to complete a registration form before 4th May: https://indico.cells.es/indico/event/28/
Download brochure (in Spanish)
